Repository logo
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. School of medicine / 醫學系
  4. Extracellular ATP Activates the PLC/PKC/ERK Signaling Pathway through the P2Y2 Purinergic Receptor Leading to the Induction of Early Growth Response 1 Expression and the Inhibition of Viability in Human Endometrial Stromal Cells.
 
  • Details
Options

Extracellular ATP Activates the PLC/PKC/ERK Signaling Pathway through the P2Y2 Purinergic Receptor Leading to the Induction of Early Growth Response 1 Expression and the Inhibition of Viability in Human Endometrial Stromal Cells.

Type
article
Resource
Cell Signal.(20):1248-1255.
Date Issued
2008
Author(s)
李怡萱
Chang SJ; Tzeng CR; Lee YH; Tai CJ
Subjects
學科:生理學科
期刊論文
Abstract
ATP is an extracellular signaling molecule that activates specific G protein-coupled P2Y receptors in most cell types to mediate diverse biological effects. ATP has been shown to activate the phospholipase C (PLC)/diacylglycerol/protein kinase C (PKC) pathway in various systems. However, little is known about the signaling events in human endometrial stromal cells (hESCs). The objective of this study was to examine the presence of the P2Y2 receptor and the effects of exogenous ATP on the intracellular mitogen-activated protein kinases (MAPKs) signaling pathway, immediate early genes expression, and cell viability in hESCs. Western blot analysis, gene array analysis, and MTT assay for cell viability were performed. The current study demonstrated the existence of the P2Y2 purinergic receptor in hESCs. UTP and ATP activated MAPK in a dose- and time-dependent manner. Suramin (a P2-purinoceptor antagonist), neomycin (a PLC inhibitor), staurosporin (a PKC inhibitor), and PD98059 (a MEK inhibitor) significantly attenuated the ATP-induced activation of MAPK. ATP activated ERK1/2 and induced translocation of activated ERK1/2 to the nucleus. The gene array for 23 genes associated with members of the mitogenic pathway cascade and immediate early genes revealed that the expression of early growth response 1 was increased. In addition, MTT assay revealed an inhibition effect of ATP on cell viability. ATP activated MAPKs through the P2Y2 purinoceptor/PLC/PKC/ERK signaling pathway and induced translocation of ERK1/2 into the nucleus. Further, ATP induced the expression of early growth response 1 and inhibited cell viability in hESCs.
URI
https://203.71.86.71/handle/123456789/30844
File(s)
Loading...
Thumbnail Image
Name

attachment.pdf

Size

1.11 MB

Format

Adobe PDF

Checksum

(MD5):37a1f0d508441e1a68e6246402e03b29

Loading...
Thumbnail Image
Name

attachment2.pdf

Size

39.28 KB

Format

Adobe PDF

Checksum

(MD5):c3e55cd4aa083266ee7c0b1eb5018118

Copyright Notice

● The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use.

● Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner. Users must not use TMUIR for any illegal purposes.

● By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in this statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions.

● TMUIR is committed to protecting the interests of copyright owners. If you believe that any material on this website infringes copyright, please contact our staff at libirtmu@gmail.com, and we will remove the work from the repository.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback